Introduction
Red blood cell (RBC) alloantibodies are formed upon exposure to allogenic RBCs expressing non-self blood group antigens via transfusion, pregnancy, or different types of transplantation. In Taiwan, the most common RBC alloantibody is anti-'Mia', followed by anti-E [1] . Why some patients develop RBC alloantibodies while others do not is not well-understood. Many recipient genetic and non-genetic factors (immunogenicity of RBC antigens, number of transfusions, underlying disease, immunosuppression, inflammatory status of the recipient) influence the propensity of transfusion recipients and pregnant women to form RBC alloantibodies [2] .
Recipient inflammation affects the frequency and magnitude of immunization to transfused RBCs [3] . In contrast to the general RBC alloimmunization rate (2.6-4.4%) [4, 5] , the rate of RBC alloimmunization in patients with sickle cell disease is considerably higher (18.6%) [6] . The antigen disparity between donor and recipient can explain in part the relatively high rate of RBC alloimmunization. Transfusions during inflammatory events were associated with increased alloantibody risk [7] . Sickle cell disease is a chronic inflammatory condition [8] . Significantly higher levels of IL-6 were observed in sickle cell disease patients than in controls [9] .
IL-6 plays a significant role in inflammation responses and the regulation of metabolic, regenerative, and neural processes [10] . IL-6 is also involved in the regulation of B-cell differentiation and immunoglobulin production [11] . IL-6 completely inhibits the generation of regulatory T cells (Tregs) induced by transforming growth factor β (TGF-β) [12] . Tregs play a role in maintaining immunological unresponsiveness to self-antigens and in suppressing excessive immune responses deleterious to the host. Tregs participate in the control of transfusion-associated RBC alloantibody responses [13] .
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IL-6 gene, located in 7p21, spans 5 kb. The IL-6 C-572G mutation in the promoter region results in substitution of guanine (G) with cytosine (C). The single nucleotide polymorphisms (SNPs) with the presence of G at position -174 (rs1800795) within the 5´ region of the IL-6 gene was found to be associated with increased donor-specific HLA antibody production after renal transplantation [14] . However, the association between IL-6 SNP and RBC alloimmunization has not been reported.
In this study, we analyzed IL-6 C-174G and IL-6 C-572G SNPs in patients and healthy subjects. This study aimed to investigate the association between SNP in IL-6 promotor and anti-E production in the blood recipients.
Material and Methods

Subjects
The total number of healthy subjects and patients is 149 (50 healthy subjects, 54 responders, and 45 non-responders). None of the 50 healthy subjects (21 women and 29 men; median age 32.5 years, range 20-58 years) had an active medical problem or evidence of abnormal hepatic or renal function according to screening laboratory test results in routine physical examination.
Patients were referred to as 'responders' if they developed clinically significant alloantibodies after two or more packed RBC transfusions. Patients with anti-E alloantibodies were recruited as responders. Non-responders were those who did not develop RBC alloantibodies after transfusing at least 15 units of packed RBCs. All patients (including responders and non-responders) were E antigen-negative. Cumulative amounts of packed RBCs transfused in responders were calculated until the first anti-RBC antibody appeared. Cumulative amounts of packed RBCs transfused in non-responders were calculated until last follow-up. The study protocol was approved by the institutional review board of Taipei Veterans General Hospital. All subjects provided informed consents.
Determination of RBC Minor Antigen and Antibodies
The minor RBC E antigen was determined by a commercial reagent (Sanquin, Amsterdam, the Netherlands) using tube method. Antibody identification was performed with commercially prepared cell panels (Sanquin) by manual polybrene test or standard tube methods in 3 phases: immediate spin, 37 ° C, and anti-IgG (Immucor Gamma Biologicals, Inc., Houston, TX, USA).
Genomic DNA Extraction and Genotyping
Genomic DNA was extracted from blood samples using the Puregene DNA isolation kit (Gentra System, Minneapolis, MN, USA) according to the method recommended by the manufacturer. The -174 G>C (rs1800795) and the -572 C>G (rs 1800796) SNPs in the promoter region of the IL-6 gene were genotyped by polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) as previously reported by Mazzatti et al. [15] . In order to screen for these SNPs of the IL-6 gene, a 617 bp fragment containing the core promotor region was amplified by PCR with the following primers: forward: 5´-AGTGGGCT-GAAGCAGGTGA-3´ and reverse: 5´-CTTTGTTGGAGGGTGAGGG-3´.
The PCR was performed in a total volume of 10 μl containing 10 ng genomic DNA, 10 mmol/l Tris-HCl (pH 8.3), 50 mmol/l KCl, 1.75 mmol/l MgCl 2 , 200 μmol/l dNTP (dATP, dCTP, dGTP, dTTP), 0.2 unit hot start AmpliTaq Gold DNA Polymerase (Applied Biosystems Inc., Foster City, CA, USA), and 2 pmol each of forward and reverse primers. The DNA template was denatured at 95 ° C for 5 min (hot start). Amplification conditions were 35 cycles of 94 ° C for 1 min, of 60 ° C for 1 min, and of 72 ° C for 5 min. The PCR products were digested at 37 ° C overnight with the enzyme NlaIII (New England Biolabs, Hitchin, UK) or BsrBI (New England Biolabs) according to the manufacture's procedure. The digested PCR product and undigested products were separated on 3.5% agarose gel electrophoresis, stained with ethidium bromide, and visualized under the ultraviolet illuminator. After reaction with NlaIII, the presence of the -174 C allele produced 4 fragments (382, 118, 87, and 29 bps) whereas the -174 G allele produced 3 fragments (382, 205, and 29 bps). Using BsrBI, the -572 C allele was not cut, whereas -572 G allele was cut into 2 fragments (486 and 131 bps).
Statistical Analysis
Deviation from Hardy-Weinberg equilibrium was tested by using the chisquare test for goodness of fit. For comparison of categorical variables between groups, the Pearson's chi-square test with Fisher's exact test was performed. The Mann-Whitney U test was used to compare numeric variables between groups.
The differences between groups were considered significant if p values of two-tails were less than 0.05. Statistical analysis was performed using IBM SPSS Statistics, Version 20 (IBM Corp. Armonk, NY, USA). The percentage of hematologic diseases in responders was significantly lower than that in non-responders (20.4 vs. 64.4%; p < 0.001). Hematologic diseases included benign diseases and malignancies.
Results
Patient Characteristics
In 54 responders, there were 11 patients (20.4%) with hematologic diseases (8 patients with benign hematologic diseases (vitamin B12 deficiency n = 1, myelodysplastic syndrome n = 5, myelofibrosis n = 2); 3 patients with hematologic malignancies (acute myeloid leukemia n = 2, chronic myeloid leukemia n = 1)), and 43 patients (79.6%) with non-hematologic diseases (uremia n = 7, solid tumors n = 12, acute anemia n = 24). 25 patients had anti-E alone, and 29 patients had anti-E with additional alloantibodies (E+c n = 13, E+Mi a n = 8, E+c+Mi a n = 3, E+Jk a n = 1, E+Di a n = 1, E+S n = 1, E+c+Jk a n = 1, E+c+Jk a +Mi a n = 1).
Of the 45 non-responders, 29 patients (64.4%) had hematologic diseases (20 patients with benign hematologic diseases (myelodysplastic syndrome n = 12, aplastic anemia n = 3, pure red cell aplasia n = 1, thalassemia n = 2, myelofibrosis n = 1, paroxysmal nocturnal hemoglobinuria n = 1); 9 patients with hematologic malignancies (acute myeloid leukemia n = 4, chronic myeloid leukemia n = 1, multiple myeloma n = 3, lymphoma n = 1) and 16 patients (35.6%) had non-hematologic diseases (uremia n = 8, solid tumors n = 6, acute anemia n = 2).
Frequencies of Genotypes and Alleles of -174G/C and -572C/G SNPs of IL-6 Gene
The distribution of genotypes for both -174C>G (rs1800795) and -572C>G (rs1800796) polymorphism did not differ from Hardy-Weinberg proportion in either patients or heathy volunteers. All patients and healthy subjects had GG at -174 position of IL-6 gene without any diversity. P 1 = Non-responders compared with responders; P 2 = healthy subjects compared with responders; P 3 = healthy subjects compared with non-responders; comparison of age was performed by the Mann-Whitney U test; comparisons between groups were performed by chi-square test and Fisher's exact test.
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The frequencies of genotypes and alleles of -572 C>G (rs1800796) polymorphism were shown in table 2. The distribution of the IL-6 -572 C>G SNP was similar between patients and healthy subjects.
Association of IL-6 -572 SNP with RBC Alloimmunization
As shown in table 2, the frequency of G allele of -572 SNP in responders was significantly higher than that in non-responders(31.5% (34/108) vs. 16.7% (15/90); p = 0.02).
Because the number of individuals with GG genotype was small, the carriers of the G allele (CG+GG) were pooled into G-positive genotype. In the responder group, 56% of the recipients carried a G-positive (CG + GG) genotype compared with 31% in the nonresponder group, (p = 0.016) (table 2). A statistically significant association was observed between the -572 IL-6 G-positive genotype and the production of RBC alloantibodies.
Patient characteristics grouped by CC genotype and G-positive (CG + GG) genotype of -572 IL-6 promoter were shown in table 1. Age, sex, disease, and amounts of packed RBCs transfused did not differ between the CC genotype and G-positive genotype of -572 IL-6 promoter (table 1). The relative risk of RBC alloimmunization in patients with G-positive genotype of -572 IL-6 SNP was significantly higher than that in patients with CC genotype (1.771 vs. 0.640; p = 0.016) (table 3) .
Discussion
In the present study, we analyzed the IL-6 genotype of two SNPs: IL-6 C-174G and IL-6 C-572G in transfusion patients and identified a strong association between G-positive genotype of IL6 C-572G SNP and alloantibody anti-E production.
Antibodies with anti-E specificity are detected in 14-20% of pregnant women [16] . The antibodies in the females could have been stimulated by transfusion or pregnancy.
Anti-E alloantibody can cause fetal anemia and delayed hemolytic transfusion reaction. We selected patients with anti-E antibody as responders because anti-E is a common clinically significant alloantibody and E antigen can be identified by a commercial kit [17] . To exclude the possibility of misdiagnosis of non-responders due to few transfusions, we defined non-responders as those who did not develop RBC alloantibody after repeated transfusions with at least 15 units of packed RBCs. So transfusion amounts were higher in non-responders than in responders. The percentage of hematologic diseases was higher in non-responders than in responders. This may be partly explained by the fact that patients with hematologic diseases were more likely to be transfusion-dependent and thus more likely to be enrolled in non-responders. The hematologic disease-associated immunosuppression, in association with immunosuppressive therapy, may also suppress alloantibody development. It is difficult to conclude whether or not hematologic diseases influence RBC alloimmunization [18] .
In this study, only the -174 GG genotype was detected. This finding is consistent with a previous report that the G-to-C polymorphism is extremely rare in Chinese [19] . In Japan only -174 GG genotype was detected, and the frequencies of -572 CC, GC and GG genotypes were 50%, 45% and 5%, respectively [20] . The distribution of genotypes of IL-6 -572 C>G SNPs in Japan was similar to our healthy subjects (table 2) (p = 0.524; data not shown).
Our study showed a higher frequency of G-positive genotypes of -572 IL-6 promoter in responders than in non-responders. The relative risk of RBC alloimmunization for patients with the -572 G-positive genotype is significantly higher than that of patients with CC genotype (p = 0.016). The -572 G-positive genotype and the CC genotype showed no differences with respect to age, sex, disease, and amounts of packed RBCs transfused. Our findings suggest a possible influence of -572 G-positive genotype on the development of RBC alloantibodies. The CC genotype is likely to affect IL-6 expression. In agreement with this notion, patients with the CC genotype has been shown to have lower serum IL-6 levels compared to those with the GG genotype [21] . Fishman et al. [22] found that the C allele was associated with significantly lower levels of plasma IL-6 in healthy subjects (GG 2.74 pg/ml, GC 2.64 pg/ml and CC 1.63 pg/ml). However, the relationship between IL-6 genotype and IL-6 serum levels is complex due to the involvement of environmental interactions [23] . The IL-6 promoter haplotype also influences IL-6 response [24] . Differences in IL-6 promoter haplotype may have an important role in determining levels of transcription for the IL-6 gene [25] .
Ma et al. [26] found that IL-6 supports CD4 differentiation into a specialized class of helper T cells for the generation of T-dependent antibody production in in vitro assays. Arneja et al. [27] demonstrated that IL-6 receptor alpha expression on T cells enhances the alloantibody responses and T-cell expansion of RBC-specific naïve T cells in response to RBC transfusions in a murine model.
The present study had several limitations. First, the sample size was limited. Second, we only assessed one polymorphism in the IL-6 gene; therefore, we cannot rule out that other polymorphisms or haplotypes in this gene might be implicated in the development of RBC alloimmunization.
In conclusion, our finding suggest that IL-6 C-572G polymorphism was significantly associated with anti-E production, with the allele G as a risk allele. Larger studies and sequencing of the whole coding sequence of the IL-6 gene would provide additional valuable data. 
